Montelukast Hexal

Montelukast, the active ingredient in Montelukast Hexal, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It blocks cysteinyl leukotriene receptors, helping to reduce airway inflammation and bronchoconstriction. The drug is indicated for the long‑term management of asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in both children and adults.

GNH USA supplies Montelukast Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑assured medicines for respiratory care and supporting patient outcomes across diverse markets.

Montelukast is a leukotriene receptor antagonist that modulates inflammatory pathways in the respiratory tract and is used to treat conditions involving airway inflammation. - Asthma: reduces airway inflammation and bronchoconstriction, helping to improve symptom control and decrease the frequency of asthma attacks. - Allergic rhinitis: alleviates nasal congestion, rhinorrhea, sneezing and itchy eyes by blocking leukotriene‑mediated inflammation in the nasal passages. - Exercise‑induced bronchoconstriction: prevents exercise‑triggered airway narrowing, allowing better tolerance of physical activity in susceptible individuals. - Prevention of asthma exacerbations: used as add‑on therapy to reduce risk of severe attacks.

Montelukast may be associated with a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate headache that may resolve without treatment. - Upper respiratory tract infection: symptoms such as sore throat, nasal congestion or mild fever. - Abdominal pain: occasional stomach discomfort, cramps or dyspepsia. - Cough: transient cough episodes, often unrelated to asthma.

Serious or Rare Side Effects: - Neuropsychiatric events: agitation, anxiety, depression, sleep disturbances or suicidal thoughts reported in rare cases. - Allergic reactions: rash, urticaria, angioedema or anaphylactic response requiring immediate medical attention. - Hepatotoxicity: elevated liver enzymes, hepatitis or jaundice, observed infrequently.

When prescribing Montelukast, clinicians should consider several precautionary measures to ensure safe use. - Assess asthma control: confirm that the patient’s asthma is stable before initiating therapy. - Monitor psychiatric symptoms: watch for mood changes, depression or suicidal ideation during treatment. - Evaluate liver function: consider baseline liver tests in patients with hepatic disease. - Use in children: adjust dosing according to age and weight as directed by the prescriber. - Contraindications: avoid use in patients with known hypersensitivity to montelukast or its excipients. - Store at ambient temperature: keep below 25°C in the original packaging, protected from moisture.

Montelukast can interact with other medicines, affecting its efficacy or safety profile.

Major Interactions (Avoid): - Phenobarbital: enzyme induction may reduce montelukast plasma levels. - Rifampin: strong CYP3A4 inducer that can lower drug exposure.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR; monitor coagulation parameters. - Antidepressants (SSRIs): possible additive neuropsychiatric effects; observe mood changes. - Beta‑agonists: concurrent use may enhance bronchodilation but requires clinical assessment.